Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/1/57 |
| _version_ | 1797520653436321792 |
|---|---|
| author | Luca Paoluzzi Thomas J Ow |
| author_facet | Luca Paoluzzi Thomas J Ow |
| author_sort | Luca Paoluzzi |
| collection | DOAJ |
| description | Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged as a highly active treatment for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC). Patients who have received an organ transplant (OTRs) have been traditionally excluded from clinical trials with checkpoint inhibitors (CIs), given concerns for organ rejection. Renal transplant recipients (RTRs) are more likely to develop cancers than the general population, and skin cancers are among the most frequent malignancies. We report the case of a 72-year-old man with a history of a kidney transplant who presented with a rapidly growing, locally advanced squamous cell carcinoma (SCC) of the scalp that recurred within four weeks from surgical resection. The patient was able to safely receive ten cycles of cemiplimab so far with significant clinical benefit, and no issues with his kidney function, while continuing immunosuppression with low dose prednisone alone. An ongoing clinical trial (NCT04339062) is further exploring the safety of CIs in patients with metastatic CSCC who have previously received allogeneic hematopoietic stem cell transplant or a kidney transplant. |
| first_indexed | 2024-03-10T07:59:40Z |
| format | Article |
| id | doaj.art-043cf9e05600458682359646e43a72d5 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T07:59:40Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-043cf9e05600458682359646e43a72d52023-11-22T11:30:45ZengMDPI AGCurrent Oncology1198-00521718-77292021-01-0128157458010.3390/curroncol28010057Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the ScalpLuca Paoluzzi0Thomas J Ow1Department of Medicine (Oncology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, NY 10467, USADepartment of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center, Bronx, New York, NY 10467, USAImmunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal antibody targeting PD1 that has recently emerged as a highly active treatment for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC). Patients who have received an organ transplant (OTRs) have been traditionally excluded from clinical trials with checkpoint inhibitors (CIs), given concerns for organ rejection. Renal transplant recipients (RTRs) are more likely to develop cancers than the general population, and skin cancers are among the most frequent malignancies. We report the case of a 72-year-old man with a history of a kidney transplant who presented with a rapidly growing, locally advanced squamous cell carcinoma (SCC) of the scalp that recurred within four weeks from surgical resection. The patient was able to safely receive ten cycles of cemiplimab so far with significant clinical benefit, and no issues with his kidney function, while continuing immunosuppression with low dose prednisone alone. An ongoing clinical trial (NCT04339062) is further exploring the safety of CIs in patients with metastatic CSCC who have previously received allogeneic hematopoietic stem cell transplant or a kidney transplant.https://www.mdpi.com/1718-7729/28/1/57cemiplimabcutaneous squamous cell carcinomakidney transplantcheckpoint inhibitorPD1 |
| spellingShingle | Luca Paoluzzi Thomas J Ow Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp Current Oncology cemiplimab cutaneous squamous cell carcinoma kidney transplant checkpoint inhibitor PD1 |
| title | Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp |
| title_full | Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp |
| title_fullStr | Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp |
| title_full_unstemmed | Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp |
| title_short | Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp |
| title_sort | safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp |
| topic | cemiplimab cutaneous squamous cell carcinoma kidney transplant checkpoint inhibitor PD1 |
| url | https://www.mdpi.com/1718-7729/28/1/57 |
| work_keys_str_mv | AT lucapaoluzzi safeadministrationofcemiplimabtoakidneytransplantpatientwithlocallyadvancedsquamouscellcarcinomaofthescalp AT thomasjow safeadministrationofcemiplimabtoakidneytransplantpatientwithlocallyadvancedsquamouscellcarcinomaofthescalp |